scholarly journals Absence of tmRNA Has a Protective Effect against Fluoroquinolones in Streptococcus pneumoniae

2017 ◽  
Vol 7 ◽  
Author(s):  
Liliana Brito ◽  
Joana Wilton ◽  
María J. Ferrándiz ◽  
Alicia Gómez-Sanz ◽  
Adela G. de la Campa ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect

scholarly journals Absence of tmRNA has a protective effect against fluoroquinolones in Streptococcus pneumoniae

2020 ◽  
Author(s):  
Liliana Brito ◽  
Joana Wilton ◽  
María José Ferrándiz ◽  
Alicia Gómez Sanz ◽  
Adela G de la Campa ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect

scholarly journals IL-6 Deficiency Exacerbates Allergic Asthma and Abrogates the Protective Effect of Allergic Inflammation against Streptococcus pneumoniae Pathogenesis

2020 ◽  
Vol 205 (2) ◽  
pp. 469-479
Author(s):  
Taylor Schmit ◽  
Sumit Ghosh ◽  
Ram Kumar Mathur ◽  
Tyler Barnhardt ◽  
Ganesh Ambigapathy ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect ◽  
Allergic Asthma ◽  
Allergic Inflammation

scholarly journals Moxifloxacin and Azithromycin but not Amoxicillin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae In Vitro when Administered up to 6 Hours after Challenge

2005 ◽  
Vol 49 (12) ◽  
pp. 5119-5122 ◽  
Author(s):  
Martina Ulrich ◽  
Cordula Albers ◽  
Jan-Georg Möller ◽  
Axel Dalhoff ◽  
Gisela Korfmann ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Epithelial Cells ◽  
Protective Effect ◽  
Respiratory Epithelial Cells ◽  
Human Respiratory Epithelial Cells ◽  
Respiratory Cells ◽  
Respiratory Epithelial

ABSTRACT We determined the protective effect of moxifloxacin, azithromycin, and amoxicillin against Streptococcus pneumoniae infection of respiratory cells. Moxifloxacin and azithromycin effectively killed intracellular S. pneumoniae strains and protected respiratory epithelial cells significantly even when given 6 h after S. pneumoniae challenge. Amoxicillin was less effective.

scholarly journals Intranasal Immunization with the Commensal Streptococcus mitis Confers Protective Immunity against Pneumococcal Lung Infection

2019 ◽  
Vol 85 (6) ◽  
Author(s):  
Sudhanshu Shekhar ◽  
Rabia Khan ◽  
Karl Schenck ◽  
Fernanda Cristina Petersen
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect ◽  
Protective Immunity ◽  
Lung Infection ◽  
Health Concern ◽  
Pneumococcal Vaccines ◽  
Pneumococcal Serotypes ◽  
Streptococcus Mitis ◽  
Content Type ◽  
Intranasal Immunization

ABSTRACT Streptococcus pneumoniae is a bacterial pathogen that causes various diseases of public health concern worldwide. Current pneumococcal vaccines target the capsular polysaccharide surrounding the cells. However, only up to 13 of more than 90 pneumococcal capsular serotypes are represented in the current conjugate vaccines. In this study, we used two experimental approaches to evaluate the potential of Streptococcus mitis, a commensal that exhibits immune cross-reactivity with S. pneumoniae, to confer protective immunity to S. pneumoniae lung infection in mice. First, we assessed the immune response and protective effect of wild-type S. mitis against lung infection by S. pneumoniae strains D39 (serotype 2) and TIGR4 (serotype 4). Second, we examined the ability of an S. mitis mutant expressing the S. pneumoniae type 4 capsule (S. mitis TIGR4cps) to elicit focused protection against S. pneumoniae TIGR4. Our results showed that intranasal immunization of mice with S. mitis produced significantly higher levels of serum IgG and IgA antibodies reactive to both S. mitis and S. pneumoniae, as well as enhanced production of interleukin 17A (IL-17A), but not gamma interferon (IFN-γ) and IL-4, compared with control mice. The immunization resulted in a reduced bacterial load in respiratory tissues following lung infection with S. pneumoniae TIGR4 or D39 compared with control mice. With S. mitis TIGR4cps, protection upon challenge with S. pneumoniae TIGR4 was superior. Thus, these findings show the potential of S. mitis to elicit natural serotype-independent protection against two pneumococcal serotypes and to provide the benefits of the well-recognized protective effect of capsule-targeting vaccines. IMPORTANCE Streptococcus pneumoniae causes various diseases worldwide. Current pneumococcal vaccines protect against a limited number of more than 90 pneumococcal serotypes, accentuating the urgent need to develop novel prophylactic strategies. S. pneumoniae and the commensal Streptococcus mitis share immunogenic characteristics that make S. mitis an attractive vaccine candidate against S. pneumoniae. In this study, we evaluated the potential of S. mitis and its mutant expressing pneumococcal capsule type 4 (S. mitis TIGR4cps) to induce protection against S. pneumoniae lung infection in mice. Our findings show that intranasal vaccination with S. mitis protects against S. pneumoniae strains D39 (serotype 2) and TIGR4 (serotype 4) in a serotype-independent fashion, which is associated with enhanced antibody and T cell responses. Furthermore, S. mitis TIGR4cps conferred additional protection against S. pneumoniae TIGR4, but not against D39. The findings highlight the potential of S. mitis to generate protection that combines both serotype-independent and serotype-specific responses.

Protective Effect of Implanted Autologous Splenic Tissue in Splenectomized Rats Exposed to i.v. Streptococcus Pneumoniae

2009 ◽  
Vol 30 (4) ◽  
pp. 367-373 ◽  
Author(s):  
Johan Lanng Nielsen ◽  
Hans M. Kerzel Andersen ◽  
Knud Bendix Hansen ◽  
Peter Saksø ◽  
Erik Skoubo Kristensen ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect ◽  
Splenic Tissue

scholarly journals Protective Effect of Plantago major L. Pectin Polysaccharide against Systemic Streptococcus pneumoniae Infection in Mice

2000 ◽  
Vol 52 (4) ◽  
pp. 348-355 ◽  
Author(s):  
G. Hetland ◽  
A. B. Samuelsen ◽  
M. Loslash, Vik ◽  
B. S. Paulsen ◽  
I. S. Aaberge ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect ◽  
Plantago Major ◽  
Pectin Polysaccharide

scholarly journals Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

1981 ◽  
Vol 153 (3) ◽  
pp. 694-705 ◽  
Author(s):  
D E Briles ◽  
M Nahm ◽  
K Schroer ◽  
J Davie ◽  
P Baker ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Protective Effect ◽  
Normal Mouse ◽  
Mouse Serum ◽  
Normal Mouse Serum ◽  
Type 3

The antiphosphocholine (PC) antibody in normal mouse sera (NMS) provides protection against intravenous infection with encapsulated strain WU2 of type 3 Streptococcus pneumoniae. Mice unable to make anti-PC antibody, as a result of suppression with anti-T-15 idiotype or inheritance of the xid gene of CAB/N mice, are highly susceptible to infection with strain WU2. Mice inheriting the xid gene can be protected with NMS from immunologically normal mice or with IgM hybridoma anti-PC antibody. The protective effect of NMS can be removed with PC-containing immunoabsorbents.

Antigenicity and protective effects of type 3 pneumococcal polysaccharide in rats

1980 ◽  
Vol 28 (3) ◽  
pp. 832-836
Author(s):  
G R Hodges ◽  
S E Worley ◽  
C E Degener ◽  
G M Clark
Keyword(s):  
Cerebrospinal Fluid ◽  
Streptococcus Pneumoniae ◽  
Antibody Response ◽  
Protective Effect ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Protective Effects ◽  
Blood Brain ◽  
Meningeal Inflammation ◽  
Type 3

The response to type 3 pneumococcal polysaccharide vaccination, the protective effect of type 3 pneumococcal polysaccharide vaccination, and the ability of hemagglutinating antibody to type 3 pneumococcal polysaccharide to cross the blood-brain barrier were studied in rats. Hemagglutinating antibody response to vaccination with type 3 pneumococcal polysaccharide was found to be dependent on the dose and route of inoculation. Intraperitoneal vaccination with type 3 pneumococcal polysaccharide protected the rats from subsequent intraperitoneal challenge with type 3 Streptococcus pneumoniae but had no effect after intracisternal challenge with type 3 S. pneumoniae. In the presence or absence of sterile meningeal inflammation, hemagglutinating antibody could not be found in cerebrospinal fluid of animals vaccinated intraperitoneally with type 3 pneumococcal polysaccharide. These results suggest that type 3 pneumococcal polysaccharide is antigenic in rats and intraperitoneal vaccination with type 3 pneumococcal polysaccharide does not protect against experimental meningitis because antibodies do not cross the blood-brain barrier.

Sign in / Sign up

Export Citation Format

Share Document